Market Overview

UPDATE: Bank of America Downgrades ResMed to Neutral on Valuation

Related RMD
ResMed Acquires Maribo Medico; Financial Terms Not Disclosed
Leader In The 'Growing' Sleep-Disordered Breathing Market Might Be Worth An Investment

Bank of America downgraded ResMed (NYSE: RMD) from Buy to Neutral.

Bank of America said, "Key result metrics of Revenue / NPAT / EPS were +4% / +2% / +2% better than BofAML and +3% / +4% / +3% stronger than Consensus. The increased Gross Margin of 61.8% (+40bps sequentially) met our forecast and beat Consensus (61.2%) reaffirming our views around product mix shift and RMD's ongoing success in the APAP category. RMD's momentum in this area is being driven by factors such as the ongoing move to Home Sleep Testing (HST), now 25% of the market, and reimbursement justification changes that are becoming based on patient compliance. Despite this, and our slight earnings upgrade, we cannot find sufficient new valuation upside to maintain our Buy call and downgrade to Neutral."

ResMed closed at $45.47 on Thursday.

Latest Ratings for RMD

Sep 2015Goldman SachsUpgradesNeutralBuy
Jul 2015Morgan StanleyUpgradesEqual-weightOverweight
Jun 2015BarclaysInitiates Coverage onEqual-weight

View More Analyst Ratings for RMD
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (RMD)

View Comments and Join the Discussion!

Get Benzinga's Newsletters